Standard BioTools and Treeline Biosciences have announced a definitive merger agreement in an all-stock transaction. The combined entity will operate as Treeline Biosciences, focusing on advancing a deep pipeline of precision oncology therapies. This strategic combination will create a well-capitalized public company with over $900 million in cash, expected to fund operations into 2029.
A Strategic Financial Combination
The merger provides Treeline with significant financial strength, adding approximately $450 million in net cash from Standard BioTools. Upon closing, the combined company is expected to have more than $900 million, securing a financial runway into 2029. Pre-merger Treeline stockholders will own approximately 84% of the new entity, with Standard BioTools stockholders holding the remaining 16%.
Advancing a Multi-Platform Pipeline
The new Treeline Biosciences will prioritize a diverse portfolio of small molecule inhibitors, protein degraders, and antibody-drug conjugates. The company currently has three programs in Phase 1 clinical trials targeting various cancers, with initial data readouts anticipated to begin in 2027. A fourth program is slated to enter the clinic in 2026, with three more expected to follow in 2027 and 2028.
Treeline's lead clinical assets include TLN-121, a protein degrader for B-cell and T-cell lymphomas showing early single-agent activity. Another key program is TLN-372, a pan-KRAS inhibitor designed for combination therapies in lung, pancreatic, and colorectal cancers. The third, TLN-254, is an EZH2 inhibitor being evaluated for its potential to treat aggressive lymphomas in combination with other agents.
Experienced Leadership and Strategic Focus
Dr. Josh Bilenker, co-founder and CEO of Treeline, will lead the combined company, bringing his experience from founding Loxo Oncology. He will be joined by Treeline’s existing executive team, including Chief Scientific Officer Dr. Jeff Engelman and Chief Financial Officer Spencer Smith. This leadership team has a proven track record in successful drug development and commercialization.
As part of the strategic shift, Treeline does not intend to operate Standard BioTools’s existing Mass Cytometry and Microfluidics businesses. Standard BioTools is actively exploring strategic options to maximize the value of these assets, including potential divestitures. This move allows the new company to focus exclusively on its therapeutic pipeline development.
Transaction Details and Timeline
The transaction, approved by both companies' boards, is expected to close in the second half of 2026. It is subject to customary closing conditions, including approval from Standard BioTools stockholders and regulatory bodies. The deal values Standard BioTools at its net cash delivered at closing plus $10 million, estimated at approximately $460 million.
This merger marks a significant step in creating a formidable, publicly traded biopharmaceutical company focused on oncology. With a robust balance sheet, an experienced leadership team, and a catalyst-rich clinical pipeline, the new Treeline Biosciences is well-positioned for future growth. The company aims to build an enduring organization dedicated to developing transformative precision medicines for patients with serious diseases.